These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
384 related articles for article (PubMed ID: 37243489)
1. Targeting the EGFR signaling pathway in cancer therapy: What's new in 2023? Halder S; Basu S; Lall SP; Ganti AK; Batra SK; Seshacharyulu P Expert Opin Ther Targets; 2023; 27(4-5):305-324. PubMed ID: 37243489 [TBL] [Abstract][Full Text] [Related]
2. Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance. Jotte RM; Spigel DR Cancer Med; 2015 Nov; 4(11):1621-32. PubMed ID: 26310719 [TBL] [Abstract][Full Text] [Related]
3. ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in Okura N; Nishioka N; Yamada T; Taniguchi H; Tanimura K; Katayama Y; Yoshimura A; Watanabe S; Kikuchi T; Shiotsu S; Kitazaki T; Nishiyama A; Iwasaku M; Kaneko Y; Uchino J; Uehara H; Horinaka M; Sakai T; Tanaka K; Kozaki R; Yano S; Takayama K Clin Cancer Res; 2020 May; 26(9):2244-2256. PubMed ID: 31953310 [TBL] [Abstract][Full Text] [Related]
4. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma. Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596 [TBL] [Abstract][Full Text] [Related]
5. Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies. Johnson M; Garassino MC; Mok T; Mitsudomi T Lung Cancer; 2022 Aug; 170():41-51. PubMed ID: 35714425 [TBL] [Abstract][Full Text] [Related]
6. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC). Hsu PC; Jablons DM; Yang CT; You L Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256 [TBL] [Abstract][Full Text] [Related]
7. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Gelatti ACZ; Drilon A; Santini FC Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888 [TBL] [Abstract][Full Text] [Related]
9. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Nguyen KS; Kobayashi S; Costa DB Clin Lung Cancer; 2009 Jul; 10(4):281-9. PubMed ID: 19632948 [TBL] [Abstract][Full Text] [Related]
10. Is there a role for dacomitinib, a second-generation irreversible inhibitor of the epidermal-growth factor receptor tyrosine kinase, in advanced non-small cell lung cancer? Bergonzini C; Leonetti A; Tiseo M; Giovannetti E; Peters GJ Expert Opin Pharmacother; 2020 Aug; 21(11):1287-1298. PubMed ID: 32292093 [TBL] [Abstract][Full Text] [Related]
12. Recent updates on the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors and resistance reversion strategies in lung cancer. Tripathi SK; Pandey K; Rengasamy KRR; Biswal BK Med Res Rev; 2020 Nov; 40(6):2132-2176. PubMed ID: 32596830 [TBL] [Abstract][Full Text] [Related]
13. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors and new therapeutic perspectives in non small cell lung cancer. Bonanno L; Jirillo A; Favaretto A Curr Drug Targets; 2011 Jun; 12(6):922-33. PubMed ID: 21443472 [TBL] [Abstract][Full Text] [Related]
14. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374 [TBL] [Abstract][Full Text] [Related]
15. [Mechanisms of Resistance to the Third-generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer]. Ni L; Nie L Zhongguo Fei Ai Za Zhi; 2018 Feb; 21(2):110-115. PubMed ID: 29526178 [TBL] [Abstract][Full Text] [Related]
16. Contribution of p53 in sensitivity to EGFR tyrosine kinase inhibitors in non-small cell lung cancer. Jung S; Kim DH; Choi YJ; Kim SY; Park H; Lee H; Choi CM; Sung YH; Lee JC; Rho JK Sci Rep; 2021 Oct; 11(1):19667. PubMed ID: 34608255 [TBL] [Abstract][Full Text] [Related]
17. Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors. Wang S; Song Y; Yan F; Liu D Front Med; 2016 Dec; 10(4):383-388. PubMed ID: 27770386 [TBL] [Abstract][Full Text] [Related]
18. Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors. Liao BC; Lin CC; Lee JH; Yang JC J Biomed Sci; 2016 Dec; 23(1):86. PubMed ID: 27912760 [TBL] [Abstract][Full Text] [Related]
19. Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy. Zhao Y; Wang H; He C J Cancer Res Clin Oncol; 2021 Dec; 147(12):3653-3664. PubMed ID: 34661758 [TBL] [Abstract][Full Text] [Related]
20. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer. Gadgeel SM; Wozniak A Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]